Premium
Amneal Pharmaceuticals Inc (AMRX)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Ms. Deborah M. AutorIndependent Director | -34,82k | 450,56k | Vente | 12,94 | 93,66k | -27,10% |
| 2026-05-07 | Mr. J. Kevin BuchiIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 337,15k | 11,52% |
| 2026-05-07 | Ms. Deborah M. AutorIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 128,48k | 37,18% |
| 2026-05-07 | Mr. Jeffrey P. GeorgeIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 344,61k | 11,24% |
| 2026-05-07 | Mr. Gautam PatelDirector | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 1,64M | 2,16% |
| 2026-05-07 | Mr. John J. KielyIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 260,25k | 15,45% |
| 2026-05-07 | Mr. Ted C. NarkIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 325,85k | 11,96% |
| 2026-05-07 | Mr. Paul M. MeisterIndependent Chairman of the Board | 48,75k | 0,00 | Derivative Exercise and Retained Stock | - | 832,80k | 6,22% |
| 2026-05-07 | Mr. Shlomo YanaiIndependent Director | 34,82k | 0,00 | Derivative Exercise and Retained Stock | - | 320,80k | 12,18% |
| 2024-11-14 | Dipan PatelInitié | -6,92M | 86,01M | Vente | 7,74 - 12,42 | 16,90M | -29,06% |
| 2026-03-03 | Mr. Chirag K. PatelCo-Founder, Co-CEO, President & Director | 535,49k | 0,00 | Derivative Exercise and Retained Stock | - | 22,66M | 2,42% |
| 2026-03-03 | Mr. Chirag K. PatelCo-Founder, Co-CEO, President & Director | -350,98k | 4,67M | Derivative Exercise and Sale | 13,30 - 13,31 | 22,66M | - |
| 2026-03-03 | Mr. Chintu PatelCo-Founder, Co-CEO & Director | 524,49k | 0,00 | Derivative Exercise and Retained Stock | - | - | - |
| 2026-03-03 | Mr. Chintu PatelCo-Founder, Co-CEO & Director | -361,98k | 4,82M | Derivative Exercise and Sale | 13,30 - 13,31 | - | - |
| 2026-03-03 | Mr. Jason B. DalyExec. VP, Chief Legal Officer & Corporate Secretary | 241,18k | 0,00 | Derivative Exercise and Retained Stock | - | 251,78k | 2 273,98% |
| 2026-03-03 | Mr. Jason B. DalyExec. VP, Chief Legal Officer & Corporate Secretary | -185,64k | 2,47M | Derivative Exercise and Sale | 13,30 - 13,31 | 251,78k | - |
| 2026-03-03 | Mr. Anastasios G. KonidarisExec. VP & CFO | 327,28k | 0,00 | Derivative Exercise and Retained Stock | - | 449,43k | 267,93% |
| 2026-03-03 | Mr. Anastasios G. KonidarisExec. VP & CFO | -306,58k | 4,08M | Derivative Exercise and Sale | 13,30 - 13,31 | 449,43k | - |
| 2026-03-03 | Ms. Nikita ShahExec. VP & Chief HR Officer | 253,39k | 0,00 | Derivative Exercise and Retained Stock | - | 399,79k | 173,08% |
| 2026-03-03 | Ms. Nikita ShahExec. VP & Chief HR Officer | -255,11k | 3,40M | Derivative Exercise and Sale | 13,30 - 13,31 | 399,79k | - |
| 2026-03-03 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | 273,65k | 0,00 | Derivative Exercise and Retained Stock | - | 426,07k | 179,53% |
| 2026-03-03 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | -275,31k | 3,66M | Derivative Exercise and Sale | 13,30 - 13,31 | 426,07k | - |
| 2025-11-17 | Mr. Ted C. NarkIndependent Director | -50,00k | 586,00k | Vente | 11,72 | 291,03k | -14,66% |
| 2025-11-12 | Ms. Nikita ShahExec. VP & Chief HR Officer | -131,86k | 1,21M | Derivative Exercise and Sale | 2,75 - 11,92 | 146,40k | - |
| 2025-10-03 | Mr. Chintu PatelCo-Founder, Co-CEO & Director | 13,26M | 0,00 | Achat | - | 25,62M | 107,26% |
| 2025-10-03 | Mr. Chintu PatelCo-Founder, Co-CEO & Director | -13,26M | 0,00 | Vente | - | 25,62M | -34,10% |
| 2025-08-27 | Mr. John J. KielyIndependent Director | -32,00k | 295,36k | Vente | 9,23 | 225,43k | -12,43% |
| 2025-08-22 | Ms. Nikita ShahExec. VP & Chief HR Officer | -120,83k | 1,17M | Vente | 9,50 - 9,66 | 146,40k | -45,22% |
| 2025-08-20 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | -175,00k | 1,16M | Derivative Exercise and Sale | 2,75 - 9,38 | 152,43k | - |
| 2025-08-20 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | -104,24k | 977,81k | Vente | 9,38 | 152,43k | -40,61% |
| 2025-08-14 | Ms. Nikita ShahExec. VP & Chief HR Officer | -71,69k | 666,04k | Vente | 9,29 | 267,24k | -21,15% |
| 2025-08-13 | Mr. Anastasios G. KonidarisExec. VP & CFO | -499,73k | 4,66M | Vente | 9,22 - 9,43 | 122,15k | -80,36% |
| 2025-08-12 | Ms. Nikita ShahExec. VP & Chief HR Officer | -50,00k | 452,00k | Vente | 9,04 | 338,93k | -12,86% |
| 2025-08-12 | Mr. Jason B. DalyExec. VP, Chief Legal Officer & Corporate Secretary | -22,00k | 199,10k | Vente | 9,05 | 10,61k | -67,47% |
| 2025-08-12 | Mr. Andrew S. BoyerExec. VP and Chief Commercial Officer of Generics & Biosciences | -33,44k | 302,60k | Vente | 9,05 | 256,67k | -11,53% |
| 2025-06-16 | Mr. Gautam PatelDirector | -94,91k | 761,15k | Automatic Disposition | 8,02 | 1,61M | -5,57% |
| 2025-06-10 | Mr. Gautam PatelDirector | -56,43k | 452,54k | Vente | 8,02 | 1,70M | -3,21% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
